- Home
- NTNX vs FBIOP Comparison
NTNX vs FBIOP Comparison
Compare NTNX & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTNX
- FBIOP
- Stock Information
- Founded
- NTNX 2009
- FBIOP N/A
- Country
- NTNX United States
- FBIOP United States
- Employees
- NTNX N/A
- FBIOP 101
- Industry
- NTNX Computer Software: Prepackaged Software
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- NTNX Technology
- FBIOP Health Care
- Exchange
- NTNX Nasdaq
- FBIOP Nasdaq
- Market Cap
- NTNX N/A
- FBIOP N/A
- IPO Year
- NTNX 2016
- FBIOP N/A
- Fundamental
- Price
- NTNX $75.10
- FBIOP $6.35
- Analyst Decision
- NTNX Buy
- FBIOP
- Analyst Count
- NTNX 13
- FBIOP 0
- Target Price
- NTNX $85.77
- FBIOP N/A
- AVG Volume (30 Days)
- NTNX 2.0M
- FBIOP N/A
- Earning Date
- NTNX 05-28-2025
- FBIOP N/A
- Dividend Yield
- NTNX N/A
- FBIOP N/A
- EPS Growth
- NTNX N/A
- FBIOP N/A
- EPS
- NTNX N/A
- FBIOP N/A
- Revenue
- NTNX $2,318,206,000.00
- FBIOP N/A
- Revenue This Year
- NTNX $19.14
- FBIOP N/A
- Revenue Next Year
- NTNX $15.55
- FBIOP N/A
- P/E Ratio
- NTNX N/A
- FBIOP N/A
- Revenue Growth
- NTNX 14.81
- FBIOP N/A
- 52 Week Low
- NTNX $43.35
- FBIOP N/A
- 52 Week High
- NTNX $79.99
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- NTNX 66.94
- FBIOP 52.45
- Support Level
- NTNX $71.20
- FBIOP $6.36
- Resistance Level
- NTNX $75.27
- FBIOP $6.80
- Average True Range (ATR)
- NTNX 1.80
- FBIOP 0.37
- MACD
- NTNX 1.22
- FBIOP -0.01
- Stochastic Oscillator
- NTNX 98.93
- FBIOP 55.97
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.